Alessandra Tedeschi

17PUBLICATIONS
69CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Cardiovascular medicine and haematology not elsewhere classifiedMolecular targetsHaematological tumoursAutoimmunity
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Feb 26, 2026
Fitness beyond age: Multidisciplinary expert opinion on redefining fitness for targeted therapies in chronic lymphocytic leukemia.

Raúl Córdoba, Stephan Stilgenbauer, Paolo Ghia

|Jan 14, 2025
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience.

Idanna Innocenti, Annamaria Tomasso, Diana Giannarelli

|Feb 16, 2024
Identifying and addressing unmet clinical needs on the use of zanubrutinib in chronic lymphocytic leukemia: A consensus-based position paper from an ad hoc expert panel.

Francesca Romana Mauro, Alessandra Tedeschi, Marzia Varettoni

|Jan 30, 2024
Ibrutinib as first line therapy in chronic lymphocytic leukemia patients over 80 years old: A retrospective real-life multicenter Italian cohort.

Enrica Antonia Martino, Francesca Romana Mauro, Gianluigi Reda

|Nov 13, 2023
Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.

Nitin Jain, Lisa J Croner, John N Allan

|Jun 07, 2023
Outcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.

John N Allan, Ian W Flinn, Tanya Siddiqi

Pageof 3

Frequent Collaborators

5 joint publications

Annamaria Frustaci

5 joint publications

Luca Laurenti

4 joint publications

Davide Rossi

4 joint publications

Marzia Varettoni